Developing a bioanalytical assay for stromal cell therapies: an interview with Laura Deedigan, Orbsen Therapeutics
In this interview, Laura Deedigan (Orbsen Therapeutics) discusses the challenges in characterizing the purity of MSCs and why this is in important in cellular therapies.
Please sign in or register for FREE
Sign in to RegMedNet
Not yet a member? Become a member FREE to:
- Get unlimited access to ALL CONTENT
- Read selected articles from journals such as Regenerative Medicine FREE
- Receive a weekly email roundup of the latest news and expert opinions
Did you know?
Your RegMedNet account also gives you access to communities on drug discovery, real-world evidence and 3D printing in medicine. Find out more>>